Retrospective analysis of the efficacy and safety of 100 mg abrocitinib in patients with moderate to severe atopic dermatitis: Real-world study.

However,in other indicators, although a certain degree of improvement was observed, the differences between groups did not reach statistical significance, suggesting that the differences between the 2 groups in these indicators might be random variations or require a larger sample size for further verification.

also in 111,027 other papers